Press release
Catheter-related Bloodstream Infection (CRBSI) Pipeline Therapies Analysis 2025: Over 5 Companies Driving Innovation Across 5+ Therapies | DelveInsight
Catheter-related Bloodstream Infection (CRBSI) Pipeline
DelveInsight's "CRBSI Pipeline Insight 2025" report delivers an in-depth evaluation of ongoing clinical research activities and future growth opportunities within the CRBSI therapeutics landscape.
The Surgical Site Infections Pipeline report offers comprehensive clinical and commercial insights into pipeline candidates ranging from preclinical and discovery stages to marketed products. It includes extensive drug profiles covering mechanisms of action, clinical trial progress, regulatory milestones such as NDA approvals (where applicable), and product development activities. These activities encompass technology platforms, partnerships, mergers and acquisitions, funding updates, regulatory designations, and other key developments related to each product.
Catheter-related Bloodstream Infection (CRBSI) Overview
Catheter-related bloodstream infection (CRBSI) refers to bacteremia that develops as a direct result of an infected intravenous catheter. It remains one of the most serious, frequent, and costly complications associated with central venous catheter use and is recognized as a major contributor to hospital-acquired bloodstream infections. Intravascular catheters play a vital role in contemporary healthcare, particularly for critically ill patients, enabling the delivery of medications, fluids, blood products, parenteral nutrition, and facilitating hemodynamic monitoring.
Among medical devices, central venous catheters (CVCs) pose the highest risk for infection and are closely linked to increased morbidity and mortality rates. These devices represent the primary source of bacteremia and septicemia in hospitalized individuals. Clinical evidence suggests that the likelihood of developing CRBSI is up to 64 times greater with CVCs compared to peripheral venous catheters, underscoring the urgent need for effective preventive and therapeutic strategies.
Request a comprehensive CRBSI pipeline insights report here: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Highlights from the CRBSI Pipeline Report
• The CRBSI pipeline showcases a competitive and evolving ecosystem, with over 5 companies developing more than 5 investigational therapies.
• Leading players, including Leonard-Meron Biosciences, Inc., along with other emerging developers, are actively assessing innovative treatment options to strengthen the CRBSI therapeutic framework.
• Notable pipeline candidates progressing through various stages of development include Mino-Lok, among others.
Recent Developments in the CRBSI Pipeline Landscape
• In December 2025, CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced interim results for the Company's ongoing real-world evidence study being conducted in conjunction with U.S. Renal Care's (USRC) use of DefenCath in adult hemodialysis patients with central venous catheters. CorMedix and USRC commenced the real-world evidence study upon outpatient commercial launch in July 2024. The study is designed to demonstrate the impact of the broad use of DefenCath in a real-world setting and prospectively assess rates of catheter-related bloodstream infections (CRBSI), as well as hospitalizations secondary to these infections. The study is designed to evaluate these data points for two years. Currently, more than 3,000 patients per month are receiving DefenCath on a routine basis at USRC facilities. CorMedix conducted a preliminary analysis of interim data for approximately 7,000 patients having received at least one dose of DefenCath in Year 1.
• In November 2024, Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company held a constructive in-person Type C meeting with the U.S. Food and Drug Administration (FDA). The meeting followed successful completion of the Company's pivotal Phase 3 clinical trial of Mino-Lok®, a novel catheter lock solution designed to salvage central venous catheters in patients suffering from central line-associated bloodstream infections (CLABSI) or catheter-related bloodstream infections (CRBSI). The primary discussion centered on responses to the FDA's questions related to Mino-Lok's clinical trial data and a pathway to a future submission.
CRBSI Pipeline Analysis
The report offers a detailed assessment covering:
• Comprehensive profiling of key companies engaged in CRBSI drug development.
• Evaluation of pipeline candidates across early, mid, and late stages of clinical development.
• Identification of companies pursuing targeted therapeutic approaches, including both active and discontinued programs.
• In-depth insights into emerging therapies based on development stage, route of administration, molecular type, mechanism of action, therapeutic approach (monotherapy or combination), and biological targets.
• Extensive analysis of strategic collaborations, licensing deals, funding activities, and partnerships between industry players and academic institutions supporting future market expansion.
Access a free sample report on CRBSI pipeline insights here: https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Catheter-Related Bloodstream Infections Competitive Landscape
Emerging CRBSI Therapies
• Mino-Lok - Leonard-Meron Biosciences, Inc.
CRBSI Key Companies
More than five major pharmaceutical and biotechnology companies are currently engaged in developing treatments for catheter-related bloodstream infections. Among these, Leonard-Meron Biosciences, Inc., along with other players, has candidates advancing into late-stage clinical development, including Phase III trials.
Catheter-Related Bloodstream Infections Therapeutic Landscape
DelveInsight's report evaluates over five products across multiple stages, including:
• Late-stage (Phase III)
• Mid-stage (Phase II)
• Early-stage (Phase I)
• Preclinical and discovery-stage candidates
• Discontinued and inactive programs
CRBSI Therapeutic Categorization
The CRBSI pipeline report provides therapeutic assessments based on route of administration, including:
• Intravenous
• Subcutaneous
• Oral
• Intramuscular
Pipeline therapies are also classified by molecular type, such as:
• Monoclonal antibodies
• Small molecules
• Peptides
Download sample pages to explore detailed insights into emerging CRBSI therapies, clinical trials, and recent advancements: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
CRBSI Pipeline Therapeutic Assessment Includes
• Assessment by product type
• Evaluation by development stage
• Analysis by route of administration
• Classification by molecule type
Download the CRBSI sample report to gain in-depth insights into the evolving CRBSI treatment market: https://www.delveinsight.com/sample-request/catheter-related-bloodstream-infection-crbsi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Catheter-related Bloodstream Infection (CRBSI) Pipeline Therapies Analysis 2025: Over 5 Companies Driving Innovation Across 5+ Therapies | DelveInsight here
News-ID: 4321791 • Views: …
More Releases from DelveInsight Business Research
Erectile Dysfunction Market Growth Outlook 2034: Epidemiology, Pipeline Therapie …
DelveInsight's "Erectile Dysfunction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Erectile Dysfunction, historical and forecasted epidemiology as well as the Erectile Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Erectile Dysfunction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Erectile Dysfunction Market Forecast
https://www.delveinsight.com/sample-request/erectile-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav
Some of the…
Degenerative Disc Disease Pipeline 2026: FDA Approvals and Clinical Trials Lands …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Degenerative Disc Disease pipeline constitutes 15+ key companies continuously working towards developing 15+ Degenerative Disc Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Degenerative Disc Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.…
Charcot Marie Tooth Disease Pipeline 2026: Therapies, MOA Insights, and Key Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Charcot Marie Tooth Disease pipeline constitutes 13+ key companies continuously working towards developing 15+ Charcot Marie Tooth Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Charcot Marie Tooth Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Stargardt Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Tria …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Stargardt Disease pipeline constitutes 20+ key companies continuously working towards developing 20+ Stargardt Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Stargardt Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
More Releases for CRBSI
CRBSI Treatment Market Is Going to Boom Rapidly | Boston Scientific • Medtroni …
The qualitative latest Research report (2026-2033) on the CRBSI Treatment Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
➤ Request a Sample Copy (Complete TOC, Tables…
Catheter-Related Bloodstream Infections (CRBSI) Market Growth Drivers, Challenge …
Catheter-related bloodstream infections (CRBSI) are infections that occur when a catheter, commonly used in medical settings for intravenous drug administration, fluid management, or monitoring, becomes contaminated with bacteria or other pathogens. These infections can lead to severe complications, including sepsis, organ failure, and even death if not treated promptly and effectively. CRBSI is a major cause of hospital-acquired infections (HAIs) and poses significant healthcare challenges worldwide. It is particularly common…
Global CRBSI Treatment Market to Experience Significant Growth to reach USD 2,90 …
The global CRBSI treatment market is on a significant growth trajectory, projected to experience a compound annual growth rate (CAGR) of 5.4% between 2025 and 2035. This growth is being propelled by multiple factors, including the rising burden of hospital-acquired infections (HAIs), increased use of central venous catheters (CVC), and continual advancements in antimicrobial therapies. These key drivers, along with ongoing innovations in infection prevention and management, are expected to…
CRBSI Treatment Market Expansion on Track to Hit US$ 2.2 Bn by 2030, Says Persis …
The catheter-related bloodstream infection (CRBSI) treatment market is witnessing steady growth, driven by the rising prevalence of healthcare-associated infections (HAIs), the increasing use of intravascular catheters, and growing awareness about infection prevention protocols. With hospitals and healthcare providers under pressure to reduce infection rates and improve patient outcomes, the market for CRBSI treatments-including antibiotics, catheters, and preventive solutions-is evolving rapidly.
✅ Get a Sample Copy of Research Report (Use Corporate…
CRBSI Treatment Market Expected to Reach USD 2.2 Billion by 2030 | Persistence M …
The global catheter-related bloodstream infection (CRBSI) treatment market is poised for significant expansion, projected to rise from US$1.5 billion in 2023 to US$2.2 billion by 2030, reflecting a CAGR of 5.7%. The market's growth is driven by the rising prevalence of chronic diseases necessitating long-term catheter use, increased healthcare expenditures, and advancements in catheter technologies.
Among the various segments, antibiotic-based treatments hold the largest share, while the echinocandin antifungal segment is…
Catheter-related bloodstream infection (CRBSI) Market Insight, Epidemiology and …
Catheter-related bloodstream infection (CRBSI) Market research report is the new statistical data source added by Infinity Business Insights.
CRBSIs (central venous catheter-related bloodstream infections) are a leading source of hospital-acquired illness, with high rates of morbidity, death, and expense. The severity of the consequences is determined by the organisms involved, the underlying pre-morbid states, the timeliness, and the suitability of the treatment/interventions received.
Note – In order to provide more accurate…
